Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin

Journal of Immunology

Volumn 177, Issue 12, 2006, Pages 8410-8421

  Charalambous, Anna ^a   Oks, Margarita ^a   Nchinda, Godwin ^a   Yamazaki, Sayuri ^a   Steinman, Ralph M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CD4 ANTIGEN; CD40 ANTIBODY; CELL RECEPTOR; CYTOKINE; DEC205 RECEPTOR ANTIBODY; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; HUMAN SURVIVIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MOUSE SURVIVIN; PLASMID DNA; POLYINOSINIC POLYCYTIDYLIC ACID; RECEPTOR ANTIBODY; SURVIVIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T CELL DEPLETION; VACCINATION;

EID: 33845425072     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.12.8410     Document Type: Article

References (89)

1. Finn, O. J. 2003. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3: 630-641.
2. Maloney, D. G., T. M. Liles, D. K. Czerwinski, C. Waldichuk, J. Rosenberg, A. Grillo-Lopez, and R. Levy. 1994. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84: 2457-2466.
3. Boye, J., T. Elter, and A. Engert. 2003. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 14: 520-535.
4. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319: 1676-1680.
5. + T cells. J. Exp. Med. 198: 569-580.
6. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA 96: 8633-8638.
7. + T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368.
8. + T cells. Immunity 22: 371-383.
9. Ribas, A., J. A. Wargo, B. Comin-Anduix, S. Sanetti, L. Y. Schumacher, C. McLean, V. B. Dissette, J. A. Glaspy, W. H. McBride, L. H. Butterfield, and J. S. Economou. 2004. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J. Immunol. 172: 4762-4769.
10. Levitsky, H. I., A. Lazenby, R. J. Hayashi, and D. M. Pardoll. 1994. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med. 179: 1215-1224.
11. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells. Immunity 12: 677-686.
12. + T lymphocytes. Nature 421: 852-856.
13. + T cells generated depends on the nature of the initial nonspecific stimulation. Eur. J. Immunol. 32: 1541-1549.
14. + T-cell response. Nat. Rev. Immunol. 4: 595-602.
15. Kaech, S. M., and R. Ahmed. 2001. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2: 415-422.
16. van Stipdonk, M. J., E. E. Lemmens, and S. P. Schoenberger. 2001. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat. Immunol. 2: 423-429.
17. + T cells after infection. Nat. Immunol. 3: 619-626.
18. + memory T cells. Nature 441: 890-893.
19. Okada, H., C. Bakal, A. Shahinian, A. Elia, A. Wakeham, W. K. Suh, G. S. Duncan, M. Ciofani, R. Rottapel, J. C. Zuniga-Pflucker, and T. W. Mak. 2004. Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J. Exp. Med. 199: 399-410.
20. Altieri, D. C. 2003. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3: 46-54.
21. Altieri, D. C. 2001. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 7: 542-547.
22. Li, F., G. Ambrosini, E. Y. Chu, J. Plescia, S. Tognin, P. C. Marchisio, and D. C. Altieri. 1998. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584.
23. Li, F., E. J. Ackermann, C. F. Bennett, A. L. Rothermel, J. Plescia, S. Tognin, A. Villa, P. C. Marchisio, and D. C. Altieri. 1999. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. 1: 461-466.
24. Uren, A. G., L. Wong, M. Pakusch, K. J. Fowler, F. J. Burrows, D. L. Vaux, and K. H. Choo. 2000. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr. Biol. 10: 1319-1328.
25. Tamm, I., Y. Wang, E. Sausville, D. A. Scudiero, N. Vigna, T. Oltersdorf, and J. C. Reed. 1998. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58: 5315-5320.
26. Grossman, D., P. I. Kim, J. S. Schechner, and D. C. Altieri. 2001. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. USA 98: 635-640.
27. Islam, A., H. Kageyama, N. Takada, T. Kawamoto, H. Takayasu, E. Isogai, M. Ohira, K. Hashizume, H. Kobayashi, Y. Kaneko, and A. Nakagawara. 2000. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19: 617-623.
28. Olie, R. A., A. P. Simoes-Wust, B. Baumann, S. H. Leech, D. Fabbro, R. A. Stahel, and U. Zangemeister-Wittke. 2000. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60: 2805-2809.
29. Dai, D. J., C. D. Lu, R. Y. Lai, J. M. Guo, H. Meng, W. S. Chen, and J. Gu. 2005. Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells. World J. Gastraenterol. 11: 193-199.
30. Blanc-Brude, O. P., M. Mesri, N. R. Wall, J. Plescia, T. Dohi, and D. C. Altieri. 2003. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin. Cancer Res. 9: 2683-2692.
31. Bonifaz, L. C., D. P. Bonnyay, A. Charalambous, D. I. Darguste, S. Fujii, H. Soares, M. K. Brimnes, B. Moltedo, T. M. Moran, and R. M. Steinman. 2004. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199: 815-824.
32. + T cell immunity at a mucosal surface after a single dose of anti-dendritic cell HIV gag fusion antibody vaccine. J. Exp. Med. 203: 607-617.
33. Boscardin, S. B., J. C. Hafalla, R. F. Masilamani, A. O. Kamphorst, H. A. Zebroski, U. Rai, A. Morrot, F. Zavala, R. M. Steinman, R. S. Nussenzweig, and M. C. Nussenzweig. 2006. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J. Exp. Med. 203: 599-606.
34. Hawiger, D., K. Inaba, Y. Dorsett, K. Guo, K. Mahnke, M. Rivera, J. V. Ravetch, R. M. Steinman, and M. C. Nussenzweig. 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194: 769-780.
35. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176: 1693-1702.
36. Heath, A. W., W. W. Wu, and M. C. Howard. 1994. Monoclonal antibodies to murine CD40 define two distinct functional epitopes. Eur. J. Immunol. 24: 1828-1834.
37. Siegel, S., A. Wagner, N. Schmitz, and M. Zeis. 2003. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br. J. Haematol 122: 911-914.
38. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor-anti-) monoclonal antibody. Cancer Res. 59: 3128-3133.
39. Jellison, E. R., S. K. Kim, and R. M. Welsh. 2005. Cutting edge: MHC class II-restricted killing in vivo during viral infection. J. Immunol. 174: 614-618.
40. Aihara, H., and J. Miyazaki. 1998. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16: 867-870.
41. Buchan, S., E. Gronevik, I. Mathiesen, C. A. King, F. K. Stevenson, and J. Rice. 2005. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. J. Immunol. 174: 6292-6298.
42. Matzinger, P., and S. Guerder. 1989. Does T-cell tolerance require a dedicated antigen-presenting cell? Nature 338: 74-76.
43. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163: 5211-5218.
44. + regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature DCs in vivo. J. Exp. Med. 198: 259-266.
45. + T cell responses to self- and mutated p53 determinants during tumorigenesis in mice. J. Immunol. 164: 5641-5651.
46. Stalder, T., S. Hahn, and P. Erb. 1994. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J. Immunol. 152: 1127-1133.
47. + CTL that utilizes a perform- rather than a Fas ligand-dependent cytotoxic mechanism. J. Immunol. 156: 153-159.
48. Spiotto, M. T., and H. Schreiber. 2005. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun. 5: 8.
49. Dubey, P., R. C. Hendrickson, S. C. Meredith, C. T. Siegel, J. Shabanowitz, J. C. Skipper, V. H. Engelhard, D. F. Hunt, and H. Schreiber. 1997. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J. Exp. Med. 185: 695-705.
50. Spiotto, M. T., M. A. Reth, and H. Schreiber. 2003. Genetic changes occurring in established tumors rapidly stimulate new antibody responses. Proc. Natl. Acad. Sci. USA 100: 5425-5430.
51. Kao, H., J. A. Marto, T. K. Hoffmann, J. Shabanowitz, S. D. Finkelstein, T. L. Whiteside, D. F. Hunt, and O. J. Finn. 2001. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J. Exp. Med. 194: 1313-1323.
52. Kessler, J. H., N. S. Beekman, S. A. Bres-Vloemans, P. Verdijk, P. A. van Veelen, A. M. Kloosterman-Joosten, D. C. Vissers, G. J. ten Bosch, M. G. Kester, A. Sijts, et al. 2001. Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen FRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193: 73-88.
53. Soares, M. M., V. Mehta, and O. J. Finn, 2001. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC-1 transgenic mice with different potential for tumor rejection. J. Immunol. 166: 6555-6563.
54. Kass, E., J. Schlom, J. Thompson, F. Guadagni, P. Graziano, and J. W. Greiner. 1999. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59: 676-683.
55. Grosenbach, D. W., J. C. Barrientos, J. Schlom, and J. W. Hodge. 2001. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 61: 4497-4505.
56. Bouneaud, C., P. Kourilsky, and P. Bousso. 2000. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal detection. Immunity 13: 829-840.
57. Gotsman, I., D. Israeli, R. Alper, E. Rabbani, D. Engelhardt, and Y. Ilan. 2002. Induction of immune tolerance toward tumor-associated-antigens enables growth of human hepatoma in mice. Int. J. Cancer 97: 52-57.
58. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49: 281-355.
59. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "Self"-reactive, Tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188: 277-286.
60. Peng, X., S. F. Hussain, and Y. Paterson. 2004. The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendriitc cell function. J. Immunol. 172: 6030-6038.
61. Gilboa, E., and J. Vieweg. 2004. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199: 251-263.
62. Bonehill, A., C. Heirman, S. Tuyaerts, A. Michiels, K. Breckpot, F. Brasseur, Y. Zhang, P. Van Der Bruggen, and K. Thielemans. 2004. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol. 172: 6649-6657.
63. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf, 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328-332.
64. Shibagaki, N., and M. C. Udey. 2003. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur. J. Immunol. 33: 850-860.
65. Srinivasan, R., A. N. Houghton, and J. D. Wolchok. 2002. Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue. Cancer Immun. 2: 8.
66. Mendiratta, S. K., G. Thai, N. K. Eslahi, N. M. Thull, M. Matar, V. Bronte, and F. Pericle. 2001. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res. 61: 859-863.
67. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327.
68. Knutson, K. L., K. Schiffman, M. A. Cheever, and M. L. Disis. 2002. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin. Cancer Res. 8: 1014-1018.
69. + T cells. J. Immunol. 165: 2287-2296.
70. Lee, K. H., E. Wang, M. B. Nielsen, J. Wunderlich, S. Migueles, M. Connors, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 1999. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163: 6292-6300.
71. Thurner, B., I. Haendle, C. Rôder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, et al. 1999. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190: 1669-1678.
72. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. D. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188: 2205-2213.
73. + T cells. J. Exp. Med. 197: 985-995.
74. Mahnke, K., M. Guo, S. Lee, H. Sepulveda, S. L. Swain, M. Nussenzweig, and R. M. Steinman. 2000. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J. Cell Biol. 151: 673-683.
75. De Smedt, T., B. Pajak, E. Muraille, L. Lespagnard, E. Heinen, P. De Baetselier, J. Urbain, O. Leo, and M. Moser. 1996. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J. Exp. Med. 184: 1413-1424.
76. + progenitor-derived dendritic cells. Cancer Immunol. Immunother. 55: 1208-1218.
77. Schroers, R., L. Shen, L. Rollins, C. M. Rooney, K. Slawin, G. Sonderstrup, X. F. Huang, and S. Y. Chen. 2003. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin. Cancer Res. 9: 4743-4755.
78. Benigni, F., V. S. Zimmermann, S. Hugues, S. Caserta, V. Basso, L. Rivino, E. Ingulli, L. Malherbe, N. Glaichenhaus, and A. Mondino. 2005. Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk. J. Immunol. 175: 739-748.
79. Fuller, M. J., and A. J. Zajac. 2003. Ablation of CD8 and CD4 T cell responses by high viral loads. J. Immunol. 170: 477-486.
80. + T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J. Exp. Med. 193: 297-306.
81. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201: 779-791.
82. + T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol. 171: 5931-5939.
83. + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2: 1.
84. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174: 2591-2601.
85. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194: 823-832.
86. + T cells to the antitumor immune response. J. Exp. Med. 201: 1591-1602.
87. Tite, J. P. 1990. Evidence of a role for TNF-anti- in cytolysis by CD4+, class II MHC-restricted cytotoxic T cells. Immunol. 71: 208-212.
88. Zeis, M., S. Siegel, A. Wagner, M. Schmitz, M. Marget, R. Kuhl-Burmeister, I. Adamzik, D. Kabelitz, P. Dreger, N. Schmitz, and A. Heiser. 2003. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J. Immunol. 170: 5391-5397.
89. Xiang, R., N. Mizutani, Y. Luo, C. Chiodoni, H. Zhou, M. Mizutani, Y. Ba, J. C. Becker, and R. A. Reisfeld. 2005. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 65: 553-561.